Robert Doebele discusses TAK-788, a first-in-class inhibitor of both EGFR and HER2 shown in an early-phase study to be active in NSCLC.
Robert Doebele, MD
Advertisement
Articles by Robert Doebele, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Why MRI Contrast Agents Are Not Interchangeable for Detecting Brain Metastases
2
FDA Gives Accelerated Approval to Sevabertinib in HER2+ NSCLC
3
FDA Withdraws Adagrasib/Cetuximab Approval in KRAS G12C-Mutated CRC
4
Durvalumab Combo Improves Survival in First-Line Extensive-Stage SCLC
5